Skip to main content

Dexcom statistics

  • DXCM · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$83.33+2.38%Close 13 Nov 2026 · Market value $30.72B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Dexcom is valued at $30.72B on its latest close. Its price is 31.0 times its earnings.

Market value$30.72B
Enterprise value$31.46B
Price / earnings31.00
Price / sales6.02
Price / book12.12
EV / EBITDA20.99
EV / sales6.16
Price / free cash flow27.97
Price / free cash flow, own 5-year average127.48
EV / EBIT25.41
EV / free cash flow28.31
Free cash flow yield3.6%

Share price

Latest close$83.33
Day's change+2.4%
52-week high$92.59
52-week low$56.72
From 52-week high−10.0%
Return · 1 month−3.1%
Return · 3 months−7.6%
Return · year to date+25.6%
Return · 1 year+39.8%
Beta · 1 year against the S&P 5000.69
50-day average$84.30
200-day average$75.08
RSI 1451.4
Average volume · 20 sessions5.0M

Margins and returns

For fiscal 2025, as filed.

Gross margin60.1%
Operating margin19.6%
Net margin17.9%
Free cash flow margin23.1%
Return on equity34.5%
Return on assets10.9%
Return on invested capital20.8%
Return on invested capital, 5-year average16.8%
Return on capital employed23.5%
Stock-based compensation / revenue3.4%

Financial position

At the end of fiscal 2025.

Cash and equivalents$917.7M
Total debt$1.34B
Net debt$418.2M
Current ratio1.88
Quick ratio0.95
Debt / equity0.49
Net debt / EBITDA0.36
Interest coverage63.76

Growth

Revenue, latest quarter on a year+11.2%
Revenue, twelve months on a year+13.0%
EPS, latest quarter on a year+2.9%
EPS, twelve months on a year+43.1%
Revenue, 5-year compound+19.3%
Revenue, 10-year compound+27.8%
Net income, 5-year compound+8.8%
Free cash flow, 5-year compound+31.3%
EPS, 5-year compound+9.5%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares406M
Shares outstanding, 5-year compound−0.7%
Net share repurchases$471.9M

Taxes

For fiscal 2025, as filed.

Income tax expense$252.1M
Effective tax rate23.2%

DXCM in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.